XML 31 R15.htm IDEA: XBRL DOCUMENT

Note 9 - Other Intangible Assets

12 Months Ended

Dec. 31, 2022

Intangible Assets Disclosure [Text Block]

NOTE 9. OTHER INTANGIBLE ASSETS

For the years ended December 31, 2022 and 2021, other intangible assets consisted of the following (in thousands):

	Balance at December 31, 2022
			Accumulated
	Gross		Amortization			Impairment			Net
Indefinite-lived intangible assets
Trade names	$	2,080	$	—		$	(970	)	$	1,110

Amortizable intangible assets
Customer relationships	$	290	$	(48	)	$	(172	)	$	70
Trade secrets / product formulations		2,890		(375	)	$	(1,415	)		1,100

Total other intangible assets	$	5,260	$	(423	)	$	(2,557	)	$	2,280

	Balance at December 31, 2021
			Accumulated
	Gross		Amortization			Impairment		Net
Indefinite-lived intangible assets
Trade names	$	2,080	$	—		$	—	$	2,080

Amortizable intangible assets
Customer relationships	$	290	$	(7	)	$	—	$	283
Trade secrets / product formulations		2,890		(53	)		—		2,837

Total other intangible assets	$	5,260	$	(60	)	$	—	$	5,200

In the fourth quarter of 2022, the Company determined that certain of its indefinite-lived and long-lived amortizable intangible assets related to its DERMAdoctor business were impaired. As such, the Company has recorded an intangible asset impairment charge of $2.6 million in the year ended December 31, 2022, which is reflected in the goodwill, intangible and other asset impairment caption in the Company’s consolidated statements of operations. The impairment information is discussed in Note 2, “Summary of Significant Account Policies,”. The Company did not record any intangible asset impairment charges for the year ended December 31, 2021.

Amortization expense was $363 thousand and $60 thousand for the years ended December 31, 2022 and 2021, respectively. Based on the amortizable intangible assets as of December 31, 2022, future amortization expenses is expected to be as follows (in thousands):

2023	$	152
2024		153
2025		152
2026		153
Thereafter		560
Total	$	1,170